Enzyme immunoassay for the quantitative determination (screening) of antibodies to Palivizumab (Synagis®) in serum and plasma with confirmation.
This kit has been especially developed for the quantitative determination of antibodies to palivizumab in serum and plasma samples.
Palivizumab (Synagis®) was associated to the development of anti-Palivizumab antibodies, even some were reported to be neutralizing, in various percentages of patients during therapy with the drug Synagis®. This might lead to severe complications. This kit can be efficiently used for monitoring anti-Palivizumab antibodies during therapy and offers the clinician a tool for decision on possible preventive measures such as possible addition of immunosuppressive drug to reduce anti-Palivizumab antibodies.
All SHIKARI® ELISA kits are suitable for biosimilar work.
All SHIKARI® ELISA kits are produced under ISO 13485 quality system and have CE IVD mark.
